RecruitingPhase 4NCT05837091
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Chad Ruoff, MDMayo Clinic
- Intervention
- Low Sodium Oxybate(drug)
- Enrollment
- 30 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2026
Study locations (4)
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- Stanford University, Redwood City, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05837091 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Harmony Biosciences Management, Inc.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited